RCS - IP Group PLC - Oxford Nanopore funding round and contract win

IPAnnouncement

13/10/2020 07:00

RNS Number : 8541B
  
IP Group PLC
  
13 October 2020
  
 




FOR RELEASE ON


13 October 2020



 
 
IP Group plc - Portfolio company Oxford Nanopore Technologies announces £84.4m of additional funding
 
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd ("Oxford Nanopore" or "the Company") has announced that it has raised an additional £84.4 million of new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen.
 
The funds will be used to support the rapid acceleration of Oxford Nanopore's commercial and manufacturing operations as well as ongoing innovation in the field of nanopore technology. The round takes the amount raised this year by Oxford Nanopore to £162.1 million, following fund raisings in January and May of £29.3 million and £48.4 million respectively.
 
Following the capital raise, IP Group has a 15.0% undiluted beneficial stake in Oxford Nanopore, valued at £257.7 million. The directors will review the carrying value of Oxford Nanopore, as usual, as part of the Group's Annual Results for 2020 in light of this funding round and all other relevant information.
 
Last week, Oxford Nanopore announced that its LamPORE test is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus that causes COVID-19, using its GridION device. Its LamPORE test is now in the process of initial rollouts in the UK, Germany, Switzerland and the United Arab Emirates.
 
The Company previously announced that it had partnered with the UK's Department of Health and Social Care with an initial order of 450,000 LamPORE SARS-CoV-2 tests and the potential to increase to millions of tests per month as indicated by the recent publication of a contract award notice of £112.6m on the TED (Tenders Electronic Daily) website. Further regulatory approvals are being pursued in other countries, including Emergency Use Authorisation in the United States, and with its partner G42 in the United Arab Emirates.
 
For more information, please contact:
 



IP Group plc


www.ipgroupplc.com




Greg Smith, Chief Financial Officer

Liz Vaughan-Adams, Communications            


+44 (0) 20 7444 0050

+44 (0) 20 7444 0062/+44 (0) 7979 853802




Charlotte Street Partners








David Gaffney


+44 (0) 7854 609998




Andrew Wilson


+44 (0) 7810 636995



 
Notes for editors
 
About IP Group
 
IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
 
Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated. 
 
For more information, please visit our website at www.ipgroupplc.com.
 
ENDS
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAGPGQPUUPUPGP